Intuitive Surgical (ISRG) Stock Price, News & Analysis

Company Overview

Founded in 1995 and headquartered in Sunnyvale, California, Intuitive Surgical, Inc. (NASDAQ: ISRG) is a global leader in robotic-assisted minimally invasive surgery. The company pioneered the da Vinci Surgical System, a robotic platform that enhances surgeons’ capabilities through high-definition 3D visualization, wristed instruments and computer-assisted precision. Since its commercial launch in 2000, the da Vinci System has been adopted by medical centers worldwide and applied to a broad range of procedures, including urology, gynecology, general surgery, thoracic and cardiothoracic interventions.

Intuitive’s product portfolio extends beyond its flagship da Vinci platform to include the Ion Endoluminal System, designed for minimally invasive biopsy in lung procedures. The company further supports its installed base with a comprehensive suite of instruments and accessories engineered for single use and multiple use, as well as software upgrades that enhance system capabilities. In addition, Intuitive offers service plans, on-site technical support and training programs for surgeons and clinical teams, aimed at optimizing clinical outcomes and operational efficiency.

Operating in more than 60 countries, Intuitive maintains a strong international presence across North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa. The company’s global infrastructure includes research and development facilities, manufacturing sites and regional training centers to support clinical adoption and post-sales services. Intuitive collaborates with healthcare institutions, key opinion leaders and medical device partners to advance robotic surgery applications and expand its therapeutic footprint.

Led by President and Chief Executive Officer Gary S. Guthart, Intuitive Surgical continues to invest in research and innovation, focusing on expanding its technology platforms and exploring new surgical domains. Through ongoing product development, regulatory approvals and clinical studies, the company aims to drive broader adoption of robotic-assisted surgery and improve patient care by enabling less invasive procedures with faster recovery times and reduced hospital stays.

Key Stats

• Today's Range: $430.34 to $448.31
• 50-Day Range: $433.66 to $500.51
• 52-Week Range: $425.00 to $616.00
• Volume: 2.50 million shs
• Average Volume: 2.67 million shs
• Market Capitalization: $157.03 billion
• P/E Ratio: 61.09
• Dividend Yield: N/A
• Price Target: $594.19
• Consensus Rating: Moderate Buy

Intuitive Surgical Stock Analysis - MarketRank™

Intuitive Surgical scored higher than 99% of companies evaluated by MarketBeat, and ranked 10th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Intuitive Surgical has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on 14 buy ratings, 6 hold ratings, and 1 sell rating.

Upside Potential

Intuitive Surgical has a consensus price target of $594.19, representing about 35.6% upside from its current price of $438.04.

Amount of Analyst Coverage

Intuitive Surgical has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 18.66%

Earnings Growth

Earnings for Intuitive Surgical are expected to grow by 18.66% in the coming year, from $6.43 to $7.63 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Intuitive Surgical is 61.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 283.46.

Price to Earnings Ratio vs. Sector

The P/E ratio of Intuitive Surgical is 61.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 77.15.

Price to Earnings Growth Ratio

Intuitive Surgical has a PEG Ratio of 4.69. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Intuitive Surgical has a P/B Ratio of 9.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.60% of the outstanding shares of Intuitive Surgical have been sold short.

Short Interest Ratio / Days to Cover

Intuitive Surgical has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Intuitive Surgical has recently increased by 5.15%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Intuitive Surgical does not currently pay a dividend.

Dividend Growth

Intuitive Surgical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.0 / 5
• Environmental Score: -1.15

Percentage of Shares Shorted

1.60% of the outstanding shares of Intuitive Surgical have been sold short.

Short Interest Ratio / Days to Cover

Intuitive Surgical has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Intuitive Surgical has recently increased by 5.15%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.15

News Sentiment

Intuitive Surgical has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 48 news articles for Intuitive Surgical this week, compared to 30 articles on an average week.

Search Interest

171 people have searched for ISRG on MarketBeat in the last 30 days. This is an increase of 272% compared to the previous 30 days.

MarketBeat Follows

46 people have added Intuitive Surgical to their MarketBeat watchlist in the last 30 days. This is an increase of 64% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Intuitive Surgical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,716,492.00 in company stock.

Percentage Held by Insiders

Only 0.70% of the stock of Intuitive Surgical is held by insiders.

Percentage Held by Institutions

83.64% of the stock of Intuitive Surgical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ISRG Stock Analysis - Frequently Asked Questions

How have ISRG shares performed this year?

Intuitive Surgical's stock was trading at $521.96 on January 1st, 2025. Since then, ISRG stock has decreased by 16.1% and is now trading at $438.04.

How were Intuitive Surgical's earnings last quarter?

Intuitive Surgical, Inc. (NASDAQ:ISRG) released its earnings results on Tuesday, July, 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.93 by $0.26. The business's revenue was up 21.4% on a year-over-year basis.
Read the conference call transcript.

When did Intuitive Surgical's stock split?

Shares of Intuitive Surgical split on Tuesday, October 5th 2021.The 3-1 split was announced on Thursday, August 5th 2021. The newly issued shares were issued to shareholders after the market closes on Monday, October 4th 2021. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

Does Intuitive Surgical have any subsidiaries?

Intuitive Surgical subsidiaries include Orpheus Medical, NeoGuide Systems, Computer Motion, Intuitive Surgical AB, Intuitive Surgical ApS, Intuitive Surgical Australia Proprietary Limited, Intuitive Surgical Brasil Importacao E Comercio De Equipamentos Cirurgicos Ltda, and more.

Who are Intuitive Surgical's major shareholders?

Top institutional investors of Intuitive Surgical include Neville Rodie & Shaw Inc., Rowlandmiller & PARTNERS.ADV, Park National Corp OH and Vigilare Wealth Management. Insiders that own company stock include David J Rosa, Marshall Mohr, Alan J Levy, Gary S Guthart, Mark J Rubash, Amal M Johnson, Jamie Samath, Jami K Nachtsheim, Brian Edward Miller, Robert Desantis, Henry L Charlton, Gary Loeb, Mark Brosius, Amy L Ladd, Fredrik Widman, Myriam Curet and Craig H Barratt.
View institutional ownership trends.

How do I buy shares of Intuitive Surgical?

Shares of ISRG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Intuitive Surgical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Intuitive Surgical investors own include BlackRock (BLK), Broadcom (AVGO), ServiceNow (NOW), NVIDIA (NVDA), UnitedHealth Group (UNH), The Goldman Sachs Group (GS) and Meta Platforms (META).

Company Calendar

• Last Earnings: 7/22/2025
• Today: 10/01/2025
• Next Earnings (Estimated): 10/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:ISRG
• CIK: 1035267
• Web: www.intuitive.com
• Phone: (408) 523-2100
• Fax: 408-523-1390
• Employees: 15,638
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Intuitive Surgical: $594.19
• High Price Target: $700.00
• Low Price Target: $440.00
• Potential Upside/Downside: +35.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.62
• Research Coverage: 21 Analysts

Profitability

• EPS (Trailing Twelve Months): $7.17
• Trailing P/E Ratio: 61.09
• Forward P/E Ratio: 68.12
• P/E Growth: 4.6
• Net Income: $2.32 billion
• Net Margins: 28.51%
• Pretax Margin: 32.60%
• Return on Equity: 14.56%
• Return on Assets: 12.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.17
• Quick Ratio: 4.18

Sales & Book Value

• Annual Sales: $9.15 billion
• Price / Sales: 17.17
• Cash Flow: $7.97 per share
• Price / Cash Flow: 54.98
• Book Value: $46.41 per share
• Price / Book: 9.44

Miscellaneous

• Outstanding Shares: 358,477,000
• Free Float: 355,968,000
• Market Cap: $157.03 billion
• Optionable: Optionable
• Beta: 1.61